Welcome to our dedicated page for ELI LILLY & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ELI LILLY & Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ELI LILLY & Co's regulatory disclosures and financial reporting.
On 08/12/2025, Director J. Erik Fyrwald reported purchases of Eli Lilly & Co. (LLY) common stock totaling 1,565 shares across two transactions: 686 shares at a weighted average price of $641.996 and 879 shares at $642.586. The Form 4 shows beneficial ownership rising to 73,698.779 shares after the first purchase and to 74,577.779 shares after the second. The filing notes the reported prices are weighted averages across multiple executions within disclosed price ranges and offers to provide detailed per-price execution data on request.
Ilya Yuffa, listed as EVP & President, LLY USA & Global Capab and an officer of Eli Lilly & Co., reported a sale of 1,250 shares of Eli Lilly common stock on 08/11/2025 at a reported price of $627.01 per share.
The Form 4 shows the sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Following the reported transaction the form lists 26,259.971 shares beneficially owned by the reporting person in a direct ownership form. No derivative transactions are reported in Table II.
Jamere Jackson, identified as a Director of Eli Lilly & Co. (LLY), reported an acquisition of 200 shares of the company’s common stock on 08/08/2025 at a reported price of $639.563 per share. The Form 4 shows his ownership following the transaction as 9,401.724 shares, held directly.
Eli Lilly (LLY) posted another record quarter. Q2-25 revenue rose 38 % YoY to $15.56 bn, driven by cardiometabolic products (Mounjaro +68 % to $5.20 bn; first-year Zepbound $3.38 bn). Oncology added $2.41 bn (+12 %).
Profitability surged. Net income nearly doubled to $5.66 bn; diluted EPS jumped 92 % to $6.29. Six-month EPS is $9.35 (+62 %). Operating margin expanded as revenue growth outpaced increases in R&D (↑23 %) and SG&A (↑30 %). No special charges occurred this quarter versus $435 m last year.
Balance-sheet trends. Total assets grew to $100.9 bn (-year-end 24: $78.7 bn) mainly from higher receivables and a $3.4 bn inventory build to support GLP-1 demand. Debt increased to $39.9 bn (-year-end: $33.6 bn) after $6.46 bn of new issuances. Cash & equivalents held steady at $3.38 bn; operating cash flow more than doubled to $4.75 bn YTD.
Capital returns & pipeline. Dividend lifted to $3.00/sh (prior-year $2.60). $13.11 bn remains on the $15 bn buyback plan. Business development continues: closed $925 m Wisconsin injectables plant (May) and, post-quarter, announced up to $2.3 bn acquisitions of Verve (cardiovascular gene therapy) and SiteOne (pain).
Outlook signals. U.S. revenue accounted for 69 % of sales; Europe grew 83 % YoY. Management highlights demand but warns of pricing, manufacturing and regulatory risks. No updated guidance included in the excerpt.
Eli Lilly and Company filed a Form 8-K dated 7 Aug 2025 under Item 2.02 to furnish, not file, a press release (Ex. 99.1) that announces the company’s financial results for the quarter ended 30 Jun 2025. The actual earnings figures are not included in this submission; investors must review the accompanying press release for details. No other material transactions or disclosures are presented. The filing re-affirms the company’s NYSE listings for its common stock and various note issues and indicates that Lilly is not an emerging-growth company. The document is purely administrative and carries no immediate financial metrics or guidance.
Eli Lilly & Co. (LLY) filed a Form 144 notice for the proposed sale of restricted shares.
- Seller intends to dispose of 280,000 common shares through Fidelity Capital Markets.
- At the filing’s reference price, the block is worth $223.7 million.
- Eli Lilly has 947.7 million shares outstanding, so the sale represents roughly 0.03 % of the float—small in relation to daily liquidity and unlikely to be dilutive.
- Planned trade date: 24 Jul 2025; exchanges listed: NYSE / NASDAQ.
- The shares trace back to a 10 Feb 1948 gift from the J.K. Lilly Sr. Trust; no other sales were reported in the past three months.
The filer certifies awareness of no undisclosed material adverse information.